PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 6, 2009, Pages 519-530

  Huang, Wenhu ^a   Yang, Amy H ^a   Matsumoto, Diane ^a   Collette, Walter ^a   Marroquin, Lisa ^a   Ko, Mira ^a   Aguirre, Shirley ^a   Younis, Husam S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ENDOTHELIAL PROTEIN C RECEPTOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; SODIUM CHLORIDE;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; CELL CULTURE; CONTROLLED STUDY; DISEASE MODEL; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG MONITORING; ENDOTHELIUM CELL; EYE EXAMINATION; EYE TOXICITY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; NONHUMAN; OXIDATIVE STRESS; PIGMENT CELL; RABBIT; RAT; RETINA ANGIOGRAPHY; RETINA BLOOD VESSEL; RETINA DEGENERATION; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA INJURY; RETINA VEIN OCCLUSION; RETINITIS; SINGLE DRUG DOSE; THROMBOGENESIS; TISSUE MICROARRAY; TREATMENT DURATION; UMBILICAL VEIN;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD; BENZAMIDES; CELLS, CULTURED; DIPHENYLAMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; FLUORESCEIN ANGIOGRAPHY; GENE EXPRESSION REGULATION; HUMANS; MALE; MICROARRAY ANALYSIS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OXIDATIVE STRESS; PROTEIN KINASE INHIBITORS; RABBITS; RATS; RATS, INBRED BN; RECEPTORS, CELL SURFACE; RETINAL VEIN OCCLUSION; SPECIES SPECIFICITY; UMBILICAL VEINS;

EID: 77149129262     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0060     Document Type: Article

References (47)

1. Chang, F., Steelman, L.S., Lee, J.T., et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 17:1263-1293, 2003.
2. Meier, F., Schittek, B., Busch, S., et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci. 10:2986-3001, 2005.
3. Shankar, S., Chen, Q., and Srivastava, R.K. Inhibition of PI3K/ AKT and MEK/ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor. J. Mol. Signal. 3:7, 2008.
4. McCubrey, J.A., Steelman, L.S., Chappell, W.H., et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773:1263-1284, 2007.
5. McCubrey, J.A., Milella, M., Tafuri, A., et al. Targeting the Raf/ MEK/ERK pathway with small-molecule inhibitors. Curr. Opin. Investig. Drugs. 9:614-630, 2008.
6. Crews, C.M., Alessandrini, A., and Erikson, R.L. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science. 258:478-480, 1992.
7. Friday, B.B., and Adjei, A.A. Advances in targeting the Ras/Raf/ MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin. Cancer Res. 14:342-346, 2008.
8. Hotte, S.J., and Hirte, H.W. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr. Pharm. Des. 8:2249-2253, 2002.
9. Malemud, C.J. Small molecular weight inhibitors of stress-activated and mitogen-activated protein kinases. Mini. Rev. Med. Chem. 6:689-698, 2006.
10. Menon, S.S., Whitfield, L.R., Sadis, S., et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients. J. Clin. Oncol. 23:3066, 2005.
11. Risk factors for central retinal vein occlusion. The Eye Disease Case-Control Study Group. Arch Ophthalmol. 114:545-554, 1996.
12. Younis, H.S., Shawer, M., Palacio, K., et al. An assessment of the ocular safety of inactive excipients following sub-tenon injection in rabbits. J. Ocul. Pharmacol. Ther. 24:206-216, 2008.
13. Lorusso, P., Krishnamurthi, S., Rinehart, J.R., et al. A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. J. Clin. Oncol. 23:3011, 2005.
14. al-Tweigeri, T., Nabholtz, J.M., and Mackey, J.R. Ocular toxicity and cancer chemotherapy. A review. Cancer. 78:1359-1373, 1996.
15. Esmaeli, B., Koller, C., Papadopoulos, N., et al. Interferon-induced retinopathy in asymptomatic cancer patients. Ophthalmology. 108:858-860, 2001.
16. Parkkari, M., Paakkala, A.M., Salminen, L., et al. Ocular sideeffects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. Acta Ophthalmol. Scand. 81:495-499, 2003.
17. Gonzalez, F., Menendez, D., and Gomez-Ulla, F. Monocular visual loss in a patient undergoing cisplatin chemotherapy. Int. Ophthalmol. 24:301-304, 2001.
18. Kwan, A.S., Sahu, A., and Palexes, G. Retinal ischemia with neovascularization in cisplatin related retinal toxicity. Am. J. Ophthalmol. 141:196-197, 2006.
19. Fraunfelder, F.T., and Meyer, S.M. Ocular toxicity of antineoplastic agents. Ophthalmology. 90:1-3, 1983.
20. Ng, W.T., Toohey, M.G., Mulhall, L., et al. Pigmentary retinopathy, macular oedema, and abnormal ERG with mitotane treatment. Br. J. Ophthalmol. 87:500-501, 2003.
21. Messersmith, W.A., Hidalgo, M., Carducci, M., et al. Novel targets in solid tumors: MEK inhibitors. Clin. Adv. Hematol. Oncol. 4:831-836, 2006.
22. Rinehart, J., Adjei, A.A., Lorusso, P.M., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22:4456-4462, 2004.
23. Adjei, A.A., Cohen, R.B., Franklin, W., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26:2139-2146, 2008.
24. Belanger, L.F., Roy, S., Tremblay, M., et al. Mek2 is dispensable for mouse growth and development. Mol. Cell. Biol. 23:4778-4787, 2003.
25. Giroux, S., Tremblay, M., Bernard, D., et al. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr. Biol. 9:369-372, 1999.
26. Jelinek, T., Catling, A.D., Reuter, C.W., et al. RAS and RAF-1 form a signalling complex with MEK-1 but not MEK-2. Mol. Cell. Biol. 14:8212-8218, 1994.
27. Guyer, D.R., Tiedeman, J., Yannuzzi, L.A., et al. Interferonassociated retinopathy. Arch Ophthalmol. 111:350-356, 1993.
28. Nadir, A., Amin, A., Chalisa, N., et al. Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature. J. Viral. Hepat. 7:466-470, 2000.
29. Romerio, F., Riva, A., and Zella, D. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/ Raf-independent mechanism. Br. J. Cancer 83:532-538, 2000.
30. Romerio, F., and Zella, D. MEK and ERK inhibitors enhance the anti-proliferative effect of interferon-alpha2b. FASEB J. 16:1680-1682, 2002.
31. Battcock, S.M., Collier, T.W., Zu, D., et al. Negative regulation of the alpha interferon-induced antiviral response by the Ras/ Raf/MEK pathway. J. Virol. 80:4422-4430, 2006.
32. Reichenbach, A., Wurm, A., Pannicke, T., et al. Muller cells as players in retinal degeneration and edema. Graefes Arch. Clin. Exp. Ophthalmol. 245:627-636, 2007.
33. Vandenbroucke, E., Mehta, D., Minshall, R., et al. Regulation of endothelial junctional permeability. Ann. N. Y. Acad. Sci. 1123:134-145, 2008.
34. Abid, M.R., Guo, S., Minami, T., et al. Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial cells. Arterioscler Thromb. Vasc. Biol. 24:294-300, 2004.
35. Lee, K.S., Park, S.J., Kim, S.R., et al. Phosphoinositide 3-kinasedelta inhibitor reduces vascular permeability in a murine model of asthma. J. Allergy Clin. Immunol. 118:403-409, 2006.
36. Serban, D., Leng, J., and Cheresh, D. H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors. Circ. Res. 102:1350-1358, 2008.
37. Herren, B., Levkau, B., Raines, E.W., et al. Cleavage of betacatenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases. Mol. Biol. Cell. 9:1589-1601, 1998.
38. Aurrand-Lions, M., Duncan, L., Ballestrem, C., et al. JAM-2, a novel immunoglobulin superfamily molecule, expressed by endothelial and lymphatic cells. J. Biol. Chem. 276:2733-2741, 2001.
39. Rehak, J., and Rehak, M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr. Eye Res. 33:111-131, 2008.
40. Lip, P.L., Blann, A.D., Jones, A.F., et al. Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye. 12(Pt 2):245-251, 1998.
41. Patrassi, G.M., Mares, M., Piermarocchi, S., et al. Fibrinolytic behavior in long-standing branch retinal vein occlusion. Ophthalmic. Res. 19:221-225, 1987.
42. Peduzzi, M., Debbia, A., Guerrieri, F., et al. Abnormal blood rheology in retinal vein occlusion. A preliminary report. Graefes Arch. Clin. Exp. Ophthalmol. 224:83-85, 1986.
43. Musashi, K., Kiryu, J., Miyamoto, K., et al. Thrombin inhibitor reduces leukocyte-endothelial cell interactions and vascular leakage after scatter laser photocoagulation. Invest. Ophthalmol. Vis. Sci. 46:2561-2566, 2005.
44. Gumus, K., Kadayifcilar, S., Eldem, B., et al. Is elevated level of soluble endothelial protein C receptor a new risk factor for retinal vein occlusion? Clin. Exp. Ophthalmol. 34:305-311, 2006.
45. Liaw, P.C., Neuenschwander, P.F., Smirnov, M.D., et al. Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. J. Biol. Chem. 275:5447-5452, 2000.
46. Saposnik, B., Reny, J.L., Gaussem, P., et al. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood. 103:1311-1318, 2004.
47. Fukudome, K., and Esmon, C.T. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J. Biol. Chem. 269:26486-26491, 1994. (Pubitemid 24328474)